Source comparison
MOTS-c vs SS-31: Research Context Determines Superiority
Primary Mechanism AMPK activation → metabolic gene expression Cardiolipin binding → cristae stabilization Entirely different pathways. Not substitutable Metabolic Syndrome / Insulin Resistance Strong preclinical evidence (diet-induced obesity models) No direct
This comparison does not assign a generated winner or score.
- Primary Mechanism
- AMPK activation → metabolic gene expression
- Cardiolipin binding → cristae stabilization
- Entirely different pathways. Not substitutable
- Metabolic Syndrome / Insulin Resistance
- Strong preclinical evidence (diet-induced obesity models)
- No direct metabolic effect
- MOTS-c is the appropriate choice
- Ischemia-Reperfusion Injury
- No protective effect demonstrated
- Preserved cardiac function in multiple trials
- SS-31 is mechanistically superior
- Neurodegenerative Disease
- Limited evidence (mostly aging models)
- Phase 2 data in LHON (vision improvement)
- SS-31 has human clinical validation
- Exercise Performance / Longevity
- Improved endurance in aged mice; circulating levels rise with exercise
- No performance benefit in healthy tissue
- MOTS-c mimics exercise adaptation pathways
- Current Regulatory Status
- Research-grade compound (not FDA-approved)
- Orphan drug designation for Barth syndrome and LHON
- SS-31 is further along the clinical approval pathway
- Our experience with researchers in this field underscores a consistent pattern: labs working on metabolic dysfunction gravitate toward MOTS-c because the AMPK pathway is the gold-standard target for insulin sensitization and metabolic flexibility. Labs studying acute mitochondrial damage (cardiac ischemia, stroke models, neurodegenerative diseases with known mitochondrial involvement) use SS-31 because cristae stabilization is the rate-limiting factor in those contexts.